Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination
Trial ID or NCT#
Phase I study of SPARC1023 alone and in combination with carboplatin
- - Age ≥18 years - ECOG Performance Status ≤ 1. - Estimated life expectancy of at least 12-weeks; - Measurable disease as per RECIST guideline (Version 1.1);
- - Any malignancy within past 5-years, except non-melanoma skin cancer, cervical intraepithelial neoplasia, or in situ cervical cancer - Known hypersensitivity to the study drugs - Treatment with any anti-cancer agents within 28 days of study entry - Presence of clinically evident active CNS metastases, including leptomeningeal involvement, requiring steroid or radiation therapy
Contact us to find out if this trial is right for you.